However, for longer treatment regimens, the dose of STING-NPs may need to be increased, the treatment regimen optimized, and/or used in combination with other immunotherapy agents to allow for robust and durable abrogation of bone tumor growth and prevention of tumor-induced bone destruction. Here, STING1 is linked to neoplasm.